The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into Phase I trials, with additional preclinical assets targeting Parkinson’s and ...

In this webinar, Ed Boyden and Jerzy Szablowski will talk about how synthetic biology can help develop tools for studying and ...

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat ...

Atalanta Therapeutics is pioneering RNA interference (RNAi) for the treatment of neurological diseases, having developed a proprietary platform that, for the first time enables RNAi to be deployed ...

The Clinic's study has already enrolled 3,600 participants, but the goal is a diverse group of 200,000. Right now, more men ...

As you lay your head down to sleep tonight and dream all things weird and wonderful, scientists think your brain is going through a gentle rinse cycle, washing away a day's worth of toxic by-products ...

A 53-year-old working professional battling dystonia has been successfully treated with advanced lesioning surgery in Mumbai. The surgery promises to offer renewed hope to him and other patients with ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

(HealthDay News) — There are disparities in traumatic brain injury (TBI)-related mortality, with the highest rates seen for older adults, men, and non-Hispanic American Indian/Alaska Native persons, ...

Immune cells called regulatory T cells have long been known for their role in countering inflammation. In the setting of ...

This accumulation could elevate their risk of developing late-onset amyloid-related disorders, such as Alzheimer’s disease.

LATE-NC diagnostic criteria improve differentiation from Alzheimer's, addressing challenges in memory-loss syndromes and ...